Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'
- PMID: 20175809
- DOI: 10.1111/j.1365-2710.2009.01044.x
Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'
Abstract
The diminution in cognitive function reported to occur in patients treated with adjuvant cancer chemotherapy (a phenomenon known as 'chemo-fog, 'chemo-brain' or similar designation) is supported with varying degrees of evidence by prospective and retrospective clinical studies. However, the cognitive deficits are often subtle and the methodologies used to measure them not consistent. Additionally, patients might be able to compensate for the deficits, thereby leading to underestimates of the problem by this type of assessment. For these reasons, direct neuroimaging techniques might provide additional insight. The relatively few such studies, and fewer electrophysiological studies, offer an alternative way to evaluate changes that might be related to cognitive deficits in patients treated with cancer chemotherapeutic regimens.
Similar articles
-
Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.J Clin Pharm Ther. 2010 Jun;35(3):249-55. doi: 10.1111/j.1365-2710.2009.01086.x. J Clin Pharm Ther. 2010. PMID: 20831527 Free PMC article.
-
Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?J Clin Pharm Ther. 2006 Apr;31(2):129-38. doi: 10.1111/j.1365-2710.2006.00726.x. J Clin Pharm Ther. 2006. PMID: 16635046 Review. No abstract available.
-
Imaging as a means of studying chemotherapy-related cognitive impairment.Adv Exp Med Biol. 2010;678:70-6. doi: 10.1007/978-1-4419-6306-2_10. Adv Exp Med Biol. 2010. PMID: 20738008 Review.
-
Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives.Semin Clin Neuropsychiatry. 2003 Oct;8(4):201-16. Semin Clin Neuropsychiatry. 2003. PMID: 14613048 Review.
-
Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment).J Clin Pharm Ther. 2013 Aug;38(4):265-8. doi: 10.1111/jcpt.12071. Epub 2013 May 8. J Clin Pharm Ther. 2013. PMID: 23656522 Free PMC article. Review.
Cited by
-
Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.BMC Cancer. 2018 Dec 7;18(1):1225. doi: 10.1186/s12885-018-5115-x. BMC Cancer. 2018. PMID: 30526520 Free PMC article.
-
Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrain").Oncotarget. 2018 Jul 13;9(54):30324-30339. doi: 10.18632/oncotarget.25718. eCollection 2018 Jul 13. Oncotarget. 2018. PMID: 30100992 Free PMC article.
-
A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog').J Clin Pharm Ther. 2011 Jun;36(3):257-9. doi: 10.1111/j.1365-2710.2010.01188.x. Epub 2010 Aug 24. J Clin Pharm Ther. 2011. PMID: 21545608 Free PMC article.
-
The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.Free Radic Biol Med. 2014 Sep;74:157-74. doi: 10.1016/j.freeradbiomed.2014.06.006. Epub 2014 Jul 1. Free Radic Biol Med. 2014. PMID: 24996204 Free PMC article. Review.
-
Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.J Clin Pharm Ther. 2011 Aug;36(4):437-45. doi: 10.1111/j.1365-2710.2010.01208.x. Epub 2010 Aug 24. J Clin Pharm Ther. 2011. PMID: 21729110 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
